To report a case of prolonged survival in a patient with advanced squamous cell lung carcinoma who experienced severe immune-related cardiotoxicity after immune checkpoint inhibitor therapy, highlighting its significance in treatment planning.
Key Findings:
The patient achieved a progression-free survival of 31 months and an overall survival of 43 months after third-line treatment, suggesting potential for extended treatment options.
Severe immune-related cardiac toxicity was successfully reversed, allowing for subsequent treatment, indicating the need for careful management of irAEs.
Interpretation:
This case suggests that anti-angiogenic therapy can be safely administered after recovery from severe immune-related cardiotoxicity in patients with advanced squamous cell lung carcinoma, warranting further investigation into its broader applicability.
Limitations:
The case study is based on a single patient, limiting generalizability and raising concerns about potential biases.
Evidence on optimal post-ICI strategies remains scarce, necessitating larger studies to validate findings.
Conclusion:
The successful management of severe immune-related cardiotoxicity in this patient underscores the importance of monitoring and managing irAEs, highlighting the potential for prolonged survival in advanced lung cancer with high PD-L1 expression.
